Citric Acid

CHEMBL1261 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
192.1 g/mol
LogP
-1.7
Phase
4

A naturally occurring tricarboxylic acid widely used in pharmaceutical formulations as an acidulant, buffering agent, antioxidant, and chelating agent. It is also used as a urinary alkalinizer in oral solutions to dissolve uric acid and cystine kidney stones. As a component of anticoagulant solutions, it binds calcium to prevent blood clotting during storage.

Molecular Weight

192.1200 g/mol

LogP

-1.70

TPSA

132.00 Ų

Lipinski RO5

Pass

Therapeutic Areas

Mechanism of Action

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)CC(O)(CC(=O)O)C(=O)O

InChI

InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

Molecular Formula

C6H8O7

HBD / HBA

4 / 7

Rotatable Bonds

5

Heavy Atoms

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A naturally occurring tricarboxylic acid widely used in pharmaceutical formulations as an acidulant, buffering agent, antioxidant, and chelating agent. It is also used as a urinary alkalinizer in oral solutions to dissolve uric acid and cystine kidney stones. As a component of anticoagulant solutions, it binds calcium to prevent blood clotting during storage.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Citric Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1261. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 311. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.